[ TRANSACTION RECORD ]

Roche Holding AG Investment in Telavant — 2023

VERIFIED VECTOR ID: 002371 · tx-346
M SOURCE NODE — FUNDER
Roche Holding AG
Healthcare Switzerland
$7,100,000,000
EQUITY
23/10/2023
Q DESTINATION NODE — RECIPIENT
Telavant
Company United States
Amount (USD)
$7.1B
Flow Type
EQUITY
Transaction Date
23/10/2023
Primary Source
View Filing ↗
Funder Profile [ M ]
Entity Roche Holding AG
AUM 255000
HQ Location Switzerland
Sector Healthcare
Recipient Profile [ Q ]
Entity Telavant
Entity Type Company
Jurisdiction United States
Intelligence Note

Roche Holding AG entered into a definitive agreement to acquire Telavant for 7.1 billion dollars to gain access to a promising therapy for inflammatory bowel disease. This transaction includes commercialization rights in the U.S. and Japan. The deal underscores Roche’s commitment to expanding its biotech portfolio.

Σ
Primary Forensic Source https://www.roche.com/media/releases/med-cor-2023-10-23/
✓ SOURCE LINKED